Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | NPY4R | P50391 | 2/20 | 0.45 |
| ▸ | REN | P00797 | 5/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31020877 | 0.93 | ACE (0.47) | ACENPY4RKISS1R | |
| SCHEMBL16507899 | 0.92 | PTPN1 (0.44) | ACEPTPN1NPY4RREN | |
| SCHEMBL13363654 | 0.90 | ACE (0.49) | ACENPY4RRENMMECPA1 | |
| SCHEMBL16507850 | 0.89 | NPY4R (0.47) | ACENPY4RRENKISS1RF2 | |
| SCHEMBL16358941 | 0.85 | ACE (0.46) | ACENPY4RMMECPA1ACE2 | |
| SCHEMBL16359347 | 0.85 | ACE (0.46) | ACENPY4RMMECPA1ACE2 | |
| SCHEMBL30670300 | 0.84 | LNPEP (0.54) | ACEMMECPA1ACE2ANPEP | |
| SCHEMBL16507783 | 0.83 | NPY4R (0.58) | NPY4RKISS1R | |
| SCHEMBL30277360 | 0.83 | F2 (0.47) | KISS1RF2 | |
| SCHEMBL16508079 | 0.83 | NPY4R (0.57) | NPY4RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | ANTHOR THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | PTH1R, MC1R, CASR | ACE 3206/4885PTPN1 826/4885NPY4R 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.